Loading...
Loading...
Browse all stories on DeepNewz
VisitGSK Agrees to $2.2 Billion Settlement Covering 93% of U.S. Zantac Lawsuits
Oct 9, 2024, 05:33 PM
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 U.S. state court cases related to its heartburn medication Zantac. The settlements encompass agreements with ten plaintiff firms, representing 93% of the product liability cases pending against the company, and are expected to be finalized by the first half of 2025. GSK will record a charge of £1.8 billion in its Q3 2024 results to account for the settlements. Additionally, the company has resolved a Qui Tam complaint for $70 million. Despite the settlements, GSK maintains that there is no consistent evidence that ranitidine, the active ingredient in Zantac, increases the risk of cancer.
View original story
Markets
No • 50%
Yes • 50%
GSK's Q3 2024 financial report
Yes • 50%
No • 50%
Court records or official GSK announcements confirming resolution of remaining lawsuits
Yes • 50%
No • 50%
Official announcements from GSK or court filings confirming the settlement finalization
Insufficient data • 25%
Stock price remains stable • 25%
Stock price decreases • 25%
Stock price increases • 25%
Stock market data from reputable financial platforms
Significant evidence found • 25%
Inconclusive • 25%
Some evidence found • 25%
No evidence found • 25%
Official statements from regulatory bodies or court rulings
Not resolved • 25%
Resolved for less than $70 million • 25%
Resolved for more than $70 million • 25%
Resolved as planned • 25%
Court records or official announcements from GSK